MedTrace Logo

Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

NCT03364400 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2023-05-15

No results posted yet for this study

Summary

This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.

Conditions

Interventions

DRUG

VT1021

Peptide

Sponsors & Collaborators

  • Vigeo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Judy Chaio, MD · Medical Director

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2024-01-31
Completion
2024-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03364400 on ClinicalTrials.gov